K-115 clinical trials
Also written Ripasudil, Glanatec and K-321.
How each study uses K-115 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the K-115 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 7
Kowa Research Institute, Inc. (4) · Stanford University (2) · Kyushu University (1) · Singapore Eye Research Institute (1) · Michael D. Straiko, MD (1) · Marian Macsai, MD (1) · University of Erlangen-Nürnberg Medical School (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test K-115, phase 3 first.
- Nov 2026Descemet Endothelial Thickness Comparison Trial IPhase 3 · Stanford University
- Oct 2027Descemet Endothelial Thickness Comparison Trial IIPhase 3 · Stanford University
Studies
Open first, then newest update. How each study uses K-115 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- The Effects of Ripasudil in Patients with FED Undergoing Femtosecond Laser Assisted Cataract SurgeryRecruitingPhase 3Singapore Eye Research InstituteNCT06048380Written as RipasudilHow we know
- Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' DystrophyRecruitingPhase 2Michael D. Straiko, MDNCT03813056Written as GlanatecHow we know
- Glanatec(R) for Descemet Stripping in Fuch's Endothelial DystrophyRecruitingPhase 4Marian Macsai, MDNCT03249337Written as Ripasudil hydrochloride hydrate 0.4% ophthalmic solutionHow we know
- Descemet Endothelial Thickness Comparison Trial IIActive, not recruitingPhase 3Stanford UniversityNCT05275972Written as RipasudilHow we know
- Descemet Endothelial Thickness Comparison Trial IActive, not recruitingPhase 3Stanford UniversityNCT05289661Written as Topical RipasudilHow we know
- A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCompletedPhase 3Kowa Research Institute, Inc.NCT05528172Written as RipasudilHow we know
- A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedPhase 3Kowa Research Institute, Inc.NCT05795699Written as RipasudilHow we know
- A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedPhase 3Kowa Research Institute, Inc.NCT05826353Written as RipasudilHow we know
- Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following DescemetorhexisCompletedPhase 2Kowa Research Institute, Inc.NCT04250207Written as K-321 SolutionHow we know
- PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of PrematurityCompletedPhase 1/2Kyushu UniversityNCT04621136Written as Ripasudil ophthalmic solution 0.4%How we know
- Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal DystrophyStatus unknownPhase 2University of Erlangen-Nürnberg Medical SchoolNCT03575130Written as Ripasudil eye dropsHow we know
Given beside what is tested · 1 — K-115 is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with K-115
- Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Aerie PharmaceuticalsNCT04620135Written as Ripasudil hydrochloride hydrate ophthalmic solution 0.4%How we know
Codes
What other systems call K-115 · ClinicalTrials.gg INT006386
- MeSH (NLM) C584679K-115One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584679 | K-115 | One source ClinicalTrials.gov |
Also registered as ripasudil (UNII 11978226XX) and ripasudil hydrochloride (UNII 016TTR32QF).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.